Product manager & clinical-affairs lead for AI medical software.
Neurology · radiotherapy.
Roadmap & strategy, design inputs, KPIs, KOL discovery — scope and prioritization for AI medical devices.
Multicenter validation studies, regulatory-grade evidence, MDR & FDA preparation, medical writing.
Computational neuroimaging, diffusion MRI, DBS targeting, imaging biomarkers from MRI & PET.
I began in physics at Yıldız Teknik in Istanbul, drawn to the precision of measurement. A master’s in biomedical engineering at Sorbonne pulled that machinery toward the body.
At the Paris Brain Institute I spent five years on the anatomo-functional organization of the subthalamic region with diffusion MRI. The question that animated my PhD was deceptively simple: when a surgeon places a DBS electrode in someone with Parkinson’s, which fibres are they actually engaging?
Answering it pulled me through tractography, phantom-based distortion evaluation at 1.5 T and 3 T, and the slow, necessary work of co-designing imaging protocols with the neurosurgeons who would use them.
In 2022 I joined TheraPanacea as a clinical analyst. Senior scientist by 2023, manager by 2024. The team now bridges research, product and regulation across our neurology and radiotherapy programmes.
Much of what I do looks like translation. I translate an F1-score into a neurologist’s diagnostic question. I translate a regulator’s clause into a study protocol. I translate a clinical workflow into a product requirement engineering can implement.
Conversations with clinicians who want to be useful in shaping a product; regulators who care about real-world performance; founders building in clinical AI who need a second pair of trained eyes on validation strategy.
A short index. Full peer-reviewed list on ORCID. Slides, recordings & press shared on request.
I read every message. I’d love to reply especially if you mention validation strategy, imaging biomarkers, AI in radiotherapy, or what it’s like to ship a CE-marked medical device.